"We have remodeled the obesity medicine opportunity based on the faster rate of uptake seen in the U.S., with our expectation that positive SELECT trial data will drive positive treatment guideline changes at the end of 2024
20,21,22 Further research is needed to investigate whether structural differences affect these mechanisms, for example, by allowing semaglutide to target a wider range of neuronal GLP-1 receptors than liraglutide
Tirzepatide vs Retatrutide The latest weight loss drug, retatrutide, differs from other weight loss medicines as it targets three hormone receptors: GLP-1, GIP, and glucagon, instead of one or two, making it potentially more effective [12]
Despite nine AOMs being currently approved for the treatment of obesity, limited clinical trial evidence in older adults predominantly focuses on incretin therapy with glucagon-like peptide-1 receptor agonists (liraglutide, semaglutide, and tirzepatide)
A higher rate of clinically significant hypoglycemic episodes was reported with the semaglutide 2.4 mg/week dose versus the 1 mg/week dose (10.7 vs
